Ingrid Roig, MD
Infectious Disease · Huntsville, ALNPI 1881847002
Payments from drug & device makers
What this record shows
5 manufacturers reported payments, led by La Jolla Pharmaceutical Company at 36.2% of the total. Reporting peaked in 2024 at $315 and has fallen 83.3% since, to $53 in 2025. That places this record below the midpoint for infectious disease clinicians in AL, where the typical reported total is $923.
Across 18 payments — averaging $35.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- La Jolla Pharmaceutical Company$234
- Insmed, Inc.$199
- Astellas Pharma US Inc$167
- Melinta Therapeutics, LLC$24
- AstraZeneca$22
Across 2 payments — averaging $6732.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$13K
What the payments were for
- Food & beverage$31649%
- Education$33151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| La Jolla Pharmaceutical Company | 2 | $234 |
| Insmed, Inc. | 12 | $199 |
| Astellas Pharma US Inc | 2 | $167 |
| Melinta Therapeutics, LLC | 1 | $24 |
| AstraZeneca | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$646 in reported general payments places this provider in the 40th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 37 | $141,996 |
| VibativTelavancin Hcl | 21 | $121,164 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $45,583 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,779 |
| IsentressRaltegravir Potassium | 13 | $29,593 |
| Daptomycin | 74 | $22,166 |
| ErtapenemErtapenem Sodium | 51 | $19,725 |
| Fosfomycin Tromethamine | 21 | $12,461 |
| Etravirine | 16 | $12,105 |
| Cefepime Hcl | 25 | $5,522 |
| Meropenem | 20 | $2,943 |
| Rifampin | 32 | $2,857 |
| Doxycycline Hyclate | 45 | $2,386 |
| Ethambutol Hcl | 25 | $1,928 |
| Vancomycin Hcl | 14 | $1,674 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Huntsville
- Ali HassounHuntsville$262K
- Scott ParkerHuntsville$11K
- Hafsa SiddiquiHuntsville$5K
- Andres Gutierrez OrdonezHuntsville$2K
- Richard SperaHuntsville$2K
- Jordan Micah PolisticoHuntsville$1K
- Tommy Parraga AcostaHuntsville$613
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Carlos Reyes-SacinMontgomery$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.